Cloud-Clone touts multi-platform antibody portfolio for research and diagnostics

Cloud-Clone says its antibody platform now spans more than 27,000 validated products and is designed for research and IVD development across multiple species and applications. The company is positioning the portfolio as a faster, more consistent source of reagents for labs and diagnostic developers worldwide.

Why it matters: - Cloud-Clone is targeting two fast-growing needs at once: research-grade antibodies and raw materials for in-vitro diagnostics. - A broader validated antibody catalog can reduce custom development time and help labs move faster from target selection to testing. - The company is also emphasizing batch consistency and cross-platform performance, two areas that matter for reproducibility and diagnostic development.

What happened: - Cloud-Clone said it has built an end-to-end antibody development platform covering polyclonal, monoclonal and recombinant antibodies. - The company said the platform is supported by 20 years of antibody R&D and manufacturing experience. - Cloud-Clone said it uses 100% in-house R&D and production, from antigen design and antibody generation to finished-product validation. - The company said its antibodies are validated for research and diagnostic use across global markets.

The details: - Cloud-Clone said its manufacturing methods include proprietary polymer adjuvants, nano-emulsification and recombinant antibody techniques. - The company said these processes are designed to reduce batch-to-batch variation and improve experimental reliability. - Cloud-Clone said it holds ISO 9001 and ISO 13485 certifications. - The company said it uses a three-level quality-control process for raw materials, intermediates and finished products. - Cloud-Clone said its antibody library includes more than 27,000 high-specificity antibodies. - The portfolio covers human, mouse, rat, rabbit, pig, bovine, goat and other species. - The company said its products support both common research targets and biomarkers used in diagnostic development. - Cloud-Clone said its antibodies are validated on WB, ELISA, IHC, IF, FCM and IP platforms. - The company said KO knockout validation is used to verify specificity. - Representative products highlighted in the release include TUBb Monoclonal Antibody (CAB870Hu22), PCNA Monoclonal Antibody (CAA591Hu22), GAL1 Polyclonal Antibody (PAA321Hu01) and OTUB1 Polyclonal Antibody (PAL838Hu01). - Cloud-Clone said it offers more than 100 multi-application antibodies including CK18, IGFBP2, NQO1 and CDKN2A. - The company said those products support work in cell proliferation, tumor biomarkers, metabolic regulation and immune modulation. - Cloud-Clone said its antibodies have been cited more than 42,000 times in SCI-indexed publications. - The company said more than 350 papers using its antibodies have appeared in journals including Nature, Science and Cell. - The company also said it offers custom antibody generation and full-cycle development services for individualized research and industry needs. - More information is available on Cloud-Clone's website.

Between the lines: - The release is as much a market-positioning statement as a product announcement. - Cloud-Clone is trying to signal that its value is not just antibody supply, but validation, manufacturing control and service breadth. - The emphasis on citations in top journals is meant to reinforce credibility with researchers and procurement teams. - The combination of research and IVD messaging suggests the company is aiming at both academic labs and commercial diagnostic developers.

What's next: - Cloud-Clone said it will keep optimizing its technical platforms and expanding its product portfolio. - The company said it plans to deliver more stable and better-adapted antibody solutions for global research and diagnostic customers. - Cloud-Clone said it wants to remain a long-term partner for scientists and industry stakeholders.

The bottom line: - Cloud-Clone is betting that scale, validation and manufacturing control will help its antibody line stand out in both research and diagnostics.